© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

Low-Dose Aspirin May Reduce Risk of Some Cancers

Photodisc
/
Thinkstock

What if an aspirin a day could keep cancer away? A growing body of scientific research suggests that aspirin can prevent some cancers of the digestive system, and maybe even breast and prostate, too.

Researchers are looking at who benefits from aspirin therapy, how much should be given, and who can tolerate it.

In the latest study, published on Thursday in the journal Cancer Epidemiology, Biomarkers & Prevention, Yale University researchers found that patients from 30 hospitals across the state were less likely to develop pancreatic cancer if they took a small, daily dose of aspirin.

Researchers are stopping short of recommending aspirin as a broad cancer prevention tool, because of its possible side effects, including stomach pain and gastrointestinal bleeding.

“Aspirin is not a risk-free substance,” said Dr. Harvey Risch, a professor of Epidemiology at the Yale School of Public Health, who led the research. People who are already taking aspirin to prevent heart attacks or fight pain should feel good that they may be reducing their cancer risk, too, he said.

Those at extra risk for colon, esophageal, or pancreatic cancer – either because of a previous bout, family history or smoking habit – may want to talk to their doctor about whether a baby aspirin a day makes sense for them, said Dr. Andrew Chan, a gastroenterologist at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School.

The same small dose – usually 81 mg a day – is often prescribed to prevent heart attacks, and researchers first discovered a connection when they noticed that people taking aspirin for heart disease did not develop as many cancers as would be expected.

A higher dose, usually taken for pain, also helps, but isn’t necessary and is more likely to bring side effects, Risch said. A lower dose may work, too, but doctors don’t yet know how low is enough or how long someone needs to take aspirin to see a cancer benefit.

Researchers aren’t entirely sure why aspirin reduces cancer risk, but presume that it helps by reducing inflammation. Other anti-inflammatory drugs like Tylenol did not show the same anti-cancer benefit in the Yale study, Risch said, probably because they work in slightly different ways.

The mounting evidence that aspirin can prevent some cancers is prompting researchers to look more carefully at who benefits from aspirin therapy, how much should be given, and who can tolerate it, said Daniel W. Rosenberg, an investigator at the Center for Molecular Medicine at the University of Connecticut Health Center in Farmington.

The new study, Rosenberg said, “adds fuel to speed that along.”

Rosenberg has been studying several thousand colon cancer patients at John Dempsey Hospital at UConn, and also found a connection between aspirin and cancer prevention.

The strongest evidence for aspirin is in colon cancer prevention, Chan said. There is substantial evidence of a benefit for esophageal and pancreatic cancer, and emerging data suggesting protection against breast and prostate cancer as well.

The Yale study, which took place from 2005 to 2009, suggested that taking aspirin cut the risk of pancreatic cancer in half, but Chan cautioned that it’s probably much less.

Risch said he is studying pancreatic cancer in patients across the state to get a better understanding of what factors may contribute to the nation’s fourth deadliest cancer – and therefore what might be done to prevent it. He’s also been looking at the role of the bacteria H. pylori, known to cause ulcers and gastric cancer, as well as smoking and alcohol use.

Prevention is a better approach than treatment or early detection for pancreatic cancer, he said, because detecting the disease a year or two earlier is unlikely to make much difference in lifespan.

This story was reported at WNPR.org under a partnership with the Connecticut Health I-Team (c-hit.org).

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content